What kind of drug is trastuzumab?

Fam-trastuzumab deruxtecan-nxki (Fam-trastuzumab deruxtecan-nxki) is a new type of anti-cancer drug used to treat HER2-positive breast cancer, non-small cell lung cancer, and gastric cancer. It is a combination of an elongation-type DNA topoisomerase I (Topo I) inhibitor and a HER2 antibody-targeted therapy.

Trastuzumab has a unique triple mechanism. First, it binds to the HER2 receptor, blocking the HER2 signaling pathway on the surface of cancer cells, preventing the proliferation and survival of cancer cells. Second, the drug connects HER2 to cytotoxic drugs through HER2 receptor-mediated endocytosis. Finally, the cytotoxic drug enters the cancer cells and is released, causing the death of the cancer cells.

Trastuzumab has shown significant efficacy in clinical trials, particularly in patients whose disease has progressed despite other treatment options. It demonstrated excellent anti-tumor activity and achieved significant results in improving patient survival and alleviating symptoms.

However, trastuzumab also has some side effects to be aware of. Common adverse reactions include nausea, vomiting, diarrhea, fatigue and leukopenia. In addition, serious adverse effects such as cardio ** may be present in some patients and require thorough evaluation and monitoring before use of this drug.

In summary, trastuzumab has great therapeutic potential as a drug targetingHER2-positive cancers. It provides a new treatment option for patients with breast or gastric cancer and offers hope for improved survival and quality of life. Despite the caveats to its side effects, the drug remains an important clinical tool for many patients.